ClinicalTrials.gg
CompletedNCT01644357Updated Sep 13, 2023

Effect of a 12-month Pharmaceutical Care Program on Control of Severe Asthma

An interventional study of Pharmaceutical care in Asthma and Quality of Life, sponsored by Federal University of Bahia. Completed at 1 site in Brazil. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-09-13.

Sponsored by Federal University of Bahia · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 138 studies in Asthma with a site in Brazil — 15 open to participants now, 18 under way, 5 of them phase 3. Asthma · Brazil.

Enrollment
99th of 125
40 · median 200
Started
2008
with 2 others
No phase
45 of 138
5 open now
Registered
45th of 138
by date

Among the 138 studies in Asthma with a site in Brazil, this one is the 99th largest by enrollment of the 125 interventional ones that give a count, is one of 3 that started in 2008, is one of 45 with no phase, and was the 45th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

15 of the 138 studies in Asthma with a site in Brazil are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Asthma with a site in Brazil, or all of them as a file.
02

Study summary

Only a few well-designed studies have investigated the effect of pharmaceutical care on asthma patients and to date there are no published studies investigating this effect specifically on severe and refractory asthma.

The objective of this study is evaluate the effect of pharmaceutical care on asthma control and quality of life (QoL) of patients with severe or refractory asthma compared with pharmacist dispensation only.

03

Conditions studied

  • Asthma
  • Quality of Life

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with severe/ asthma presenting other respiratory disease,
  • ≥ 18 years of age,
  • using high dose of inhaled (≥ 800mcg of budesonide or equivalent)
  • \<60%,
  • regular visitor of the pharmacy and the physicians.

Exclusion criteria

Exclusion Criteria:

  • participation in other intervention study during this study,
  • living in other cities,
  • could not participate in all visits of the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • No intervention
    Dispensing only

    Non clinical pharmacists will dispense drugs to patients and usual care will be offered.

  • Experimental
    Pharmaceutical care

    Patients on experimental group will receive counseling and education on the asthma condition, medication and lifestyle issues. In all visits, the inhaler technique will be reviewed, adherence to treatment and drug related problems were checked. If necessary the patient will be referred to the respiratory specialist to change the medication or to prescribe dose adjustment. Pharmacists document their initial and monthly follow up encounters using a specified form.

    Other: Pharmaceutical care

Interventions

  • OtherPharmaceutical care

    Pharmacist intervention, focused on the optimization of drug therapy, identification and resolution of drug related problems, resulting in best asthma control and quality of life. Pharmacists document their initial and monthly follow up encounters using a specified form. An action plan for self management of these patients was prepared and discussed aiming at early identification and treatment of an exacerbation episode. Meetings will be held weekly with intervention team to discuss action plan and measure of outcomes of all problems identified.

06

What researchers measure

Primary outcomes

  1. asthma control of symptoms

    Measured by Asthma Control Questionnaire and medical evaluation

    Time frame: 12 months

Other outcomes

  1. Lung function improvement

    Measured by spirometry

    Time frame: 12 months

  2. Quality of life improvement

    Measured by Asthma Quality of Life questionnaire

    Time frame: 12 months

07

Study locations

1 site
  • Program for Asthma Control (ProAR) of the Federal University of Bahia
    Salvador, Bahia 40060-330, Brazil
08

References and documents

Individual participant data

Plan to share: No — Publish a paper in a cientific journal

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Aug 2011 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2012
First posted
Jul 19, 2012
Start
Aug 2008
Primary completionActual
Aug 2011
CompletionActual
Jul 2014
Last update
Sep 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01644357
Lead sponsor
Federal University of Bahia
Collaborators
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Responsible party
Pablo de Moura Santos (Pharmacist, Federal University of Bahia) — Principal investigator
First posted
Jul 19, 2012
Start date
Aug 2008
Primary completion
Aug 2011
Completion
Jul 2014
Last update
Sep 13, 2023

Study contacts

Pablo M Santos, Master
principal investigator · Federal University of Bahia
Álvaro A Cruz, Professor
study director · Federal University of Bahia
Lúcia B Noblat, Professor
study chair · Federal University of Bahia

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion